BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results

BioCryst Pharma (BCRX) Reports In-Line Q4 EPS, Revenues Miss

March 4, 2019 7:13 AM EST

BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.25), in-line with the analyst estimate of ($0.25). Revenue for the quarter came in at $2.73 million versus the consensus estimate of $2.82 million.

In a year with many transformative milestones for BioCryst, it has been exciting to see so much progress already in the first two months of the year. The strong Phase 2 clinical data from our now-completed ZENITH-1 trial... More